An immunological view of chemotherapy

Immunotherapy

Volumn 7, Issue 9, 2015, Pages 941-943

  Tsung, Kangla ^a   Norton, Jeffrey A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antitumor immunity; autoimmunity; chemotherapy; CTLA 4 Ig; DAMP; foreign antigen; IL 12; metastases; PD1 PDL1; Treg

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 12; PATTERN RECOGNITION RECEPTOR;

ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DOWN REGULATION; DRUG EFFICACY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPLEEN CELL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION; TUMOR VOLUME; ANIMAL; DRUG EFFECTS; DRUG THERAPY; IMMUNITY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS;

ANIMALS; COMBINED MODALITY THERAPY; DRUG THERAPY; HUMANS; IMMUNITY; IMMUNOTHERAPY; INTERLEUKIN-12; NEOPLASMS; RECEPTORS, PATTERN RECOGNITION; T-LYMPHOCYTES;

EID: 84947604506     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.62     Document Type: Review

References (17)

1. Ferrer JF, Mihich E. Dependence of the regression of sarcoma 180 in vitamin B 6-deficient mice upon the immunologic competence of the host. Cancer Res. 27(3), 456-461 (1967).
2. Moore M, Williams DE. Contribution of host immunity to cyclophosphamide therapy of a chemically-induced murine sarcoma. Int. J. Cancer 11(2), 358-368 (1973).
3. Radov LA, Korn JH, Haskill JS. Host immune potentiation of drug responses to a murine mammary adenocarcinoma. II. Effect of melphalan therapy on the host immune system. Int. J. Cancer 18(5), 630-638 (1976).
4. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13(9), 1050-1059 (2007).
5. Zhang L, Feng D, Yu LX et al. Preexisting antitumor immunity augments the antitumor effects of chemotherapy. Cancer Immunol. Immunother. 62(6), 1061-1071 (2013).
6. Ostrand-Rosenberg S, Grusby MJ, Clements VK. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol. 165(11), 6015-6019 (2000).
7. Zhang L, Feng D, Hu Y et al. IL-12 augments antitumor responses to cycled chemotherapy. J. Immunother. 38(4), 137-144 (2015).
8. Huang X, Yang Y. The fate of effector CD8 T cells in vivo is controlled by the duration of antigen stimulation. Immunology 118(3), 361-371 (2006).
9. Ochsenbein AF, Klenerman P, Karrer U et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl Acad. Sci. USA 96(16), 2233-2238 (1999).
10. Webb S, Morris C, Sprent J. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 63(6), 1249-1256 (1990).
11. Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GMCSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190(3), 355-366 (1999).
12. Zinkernagel RM. Localization dose and time of antigens determine immune reactivity. Semin. Immunol. 12(3), 163-171; discussion 257-344 (2000).
13. Tsung K, Meko JB, Tsung YL et al. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. J. Immunol. 160(3), 1369-1377 (1998).
14. Le HN, Lee NC, Tsung K et al. Pre-existing tumorsensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12. J. Immunol. 167(12), 6765-6772 (2001).
15. Ruby CE, Montler R, Zheng R et al. IL-12 is required for anti-OX40-mediated CD4 T cell survival. J. Immunol. 180(4), 2140-2148 (2008).
16. Valenzuela JO, Hammerbeck CD, Mescher MF. Cutting edge: Bcl-3 up-regulation by signal 3 cytokine (IL-12) prolongs survival of antigen-activated CD8 T cells. J. Immunol. 174(2), 600-604 (2005).
17. King IL, Segal BM. Cutting edge: IL-12 induces CD4+CD25-T cell activation in the presence of T regulatory cells. J. Immunol. 175(2), 641-645 (2005).